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Biomarkers for Parkinson’s disease (PD) are mainly intended for the early diagnosis of the disease 
and to monitor its progression, two aspects insufficiently covered by clinical evaluation. In the 
last 20 years, the search for biomarkers has been supported by technological advances in the 
fields of molecular genetics and neuroimaging. Nevertheless, no fully validated biomarker is yet 
available, and there is still a need for biomarkers that will complement those already available. 
Development of biomarkers for PD has been hampered by the fact that the core pathology 
lies in the brainstem, hidden from direct study in living patients. In this context, the recent 
observations that clearly demonstrated the presence of PD pathology in peripheral neural tissues 
provide new opportunities to develop original histopathological markers of the disease. Some 
of these peripheral tissues, especially the enteric nervous system, by being assessable using 
routine biopsies, could represent a window to assess in vivo the neuropathological processes 
occurring in PD.
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symptoms, especially dementia, are known to occur lately in the 
 evolution of the disease and to reflect disease progression and sever-
ity (Chaudhuri et al., 2006).
Currently, diagnosis and progression of PD is based mainly on 
clinical criteria. Diagnosis of PD relies on the presence of two out 
of three of major motor signs, namely tremor, bradykinesia, and 
hypertonia, implying that the diagnosis is made only many years 
after the real onset of the neurodegenerative process (Hughes et al., 
2002). PD can be difficult to diagnose in its early stages, and may 
be mimicked by other diseases, such as essential tremor, multiple 
system atrophy and progressive supranuclear palsy (Hughes et al., 
2002). Treatment strategies for PD are mostly aimed at reliev-
ing motor symptoms and not at modifying the disease process 
(Thobois et al., 2005). Therefore, a key goal in PD research is the 
development of drugs capable of preventing or at least slowing the 
disease progression. Compounding this problem is the difficulty to 
readily assess PD progression and/or severity. To date, most of the 
neuroprotective trials in PD used changes in the clinical UPDRS 
scale as a primary endpoint (Schapira and Olanow, 2004; Olanow 
et al., 2009). Such an approach is confounding since many of the 
drugs proposed to slow progression also improve dopaminer-
gic neurotransmission and treat PD symptoms (Ahlskog, 2007). 
Consequently, there is a critical need to develop biomarkers that 
correlate either with the presence or the severity of the disease, for 
a more precise and early diagnosis of the disease as well as for the 
assessment of new therapeutic strategies (Figure 1). Technological 
advances in the field of molecular genetics and in in vivo imaging 
have allowed the development of some reliable biomarkers either 
for early diagnosis or to assess disease progression. For instance, 
transcranial ultrasound (Berg and Becker, 2002), high-field MRI 
Development of biomarkers for PD has been hampered by the fact 
that the core pathology lies in the brainstem, hidden from direct 
study in living patients. However the traditional assumption of PD 
as a primary disorder of the dopaminergic neurons of the substantia 
nigra has been reconsidered in the recent years. Recent studies have 
indeed implicated that the presence of Lewy pathology is much 
more extensive and affects not only the central nervous system but 
also peripheral autonomic neuronal circuits. This provides new 
opportunities for the development of original biomarkers that will 
directly assess the pathological process in peripheral tissues acces-
sible by biopsy.
In search of bIomarkers for PD
Parkinson’s disease (PD) is a progressive neurodegenerative con-
dition characterized and diagnosed by the presence of motor and 
non-motor symptoms (Lees et al., 2009). From a pathological 
point of view, the two hallmarks of PD are a loss of dopaminergic 
neurons in the substantia nigra and the presence in the surviving 
neurons of inclusions termed Lewy bodies (LB) and Lewy neurites 
(LN), whose main component is phosphorylated alpha-synuclein 
(Fujiwara et al., 2002; Anderson et al., 2006).
Parkinson’s disease follows a slowly chronic progressive course, 
and the motor cardinal symptoms of the disease appear only when 
the degenerative process has progressed for a long time, in most 
cases probably for more than 10 years (Hawkes et al., 2009). This 
long premotor phase is nevertheless not clinically silent since non-
motor symptoms such as hyposmia (Ponsen et al., 2004), REM-
sleep behavior disorder (Postuma et al., 2009), and constipation 
(Abbott et al., 2001; Savica et al., 2009) can antedate the occur-
rence of tremor and/or akinesia. In contrast, other non-motor 
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neuronal circuits (Wakabayashi et al., 1988, 1993; Wakabayashi and 
Takahashi, 1997; Braak et al., 2006, 2007; Braak and Del Tredici, 
2008). Interestingly, the same temporal pattern of degeneration has 
been demonstrated in peripheral structures such as sympathetic 
ganglia (Orimo et al., 2008).
Lewy pathology has been reported to be present in the olfactory 
bulbs of subjects with PD as well as a subset of asymptomatic sub-
jects. The presence of Lewy inclusions in neurologically unimpaired 
patients is called incidental Lewy body disease (ILBD; DelleDonne 
et al., 2008), since it is thought to represent premotor PD (Del 
Tredici et al., 2002; Braak et al., 2003; Beach et al., 2010). A recent 
comprehensive survey has shown that LB were readily retrieved 
in the olfactory bulbs of 55 out of 58 autopsied patients with PD 
(Beach et al., 2010). The involvement of the olfactory bulb in most 
ILBD patients suggests that it occurs at the earliest stage of disease 
(Bloch et al., 2006; Beach et al., 2009).
The autonomic nervous system (ANS), composed of parasym-
pathetic and sympathetic division, is distributed to the peripheral 
tissues and organs by way of autonomic ganglia. Control centers 
of the diencephalon and brainstem send fibers to synapse on pre-
ganglionic neurons located in the brainstem or in the spinal cord. 
From these neurons, preganglionic fibers project out of the CNS 
to synapse on neurons in the autonomic ganglia. Postganglionic 
fibers emerge and form terminal networks on the target tissue. 
The enteric nervous system (ENS) could be considered part of 
(Martin et al., 2008) and dosage of neuronal protein involved in 
the pathogenesis of the disease in the cerebrospinal fluid (Hong 
et al., 2010) are new tools that are likely to help in the diagnosis 
and management of PD patients in the near future. Nevertheless, 
as stated in a recent review, no fully validated biomarker for PD is 
available yet (Marek et al., 2008) and there is still a need for new 
biomarkers that will complement the ones already available.
PD Pathology extenDs well beyonD  
the substantIa nIgra
The traditional assumption of PD as a primary disorder of the 
dopaminergic neurons of the SN has been reconsidered in recent 
years. The SN is neither the earliest nor the most severely affected 
region since more caudal brainstem structures as well as the olfac-
tory bulb are involved earlier and more severely in most cases (Del 
Tredici et al., 2002; Braak et al., 2003). Nuclei such as the dorsal 
motor nucleus of the vagus nerve display early and massive degen-
erative changes that worsen as the disease progresses, until a total 
neuronal loss is reached (Braak et al., 2002). The density of LB and 
LN in brainstem nuclei is thought to follow an inverted U-shaped 
curve, with a progressive disappearance in end-stages where no 
vulnerable neurons are left.
Furthermore, recent studies have demonstrated that the pres-
ence of Lewy pathology is much more extensive and affects not only 
the central nervous system (CNS) but also peripheral autonomic 
Figure 1 | The three purposes of biomarkers in Parkinson’s disease. 
Schematic representation of the clinical progression of Parkinson’s disease (PD). 
The thin line represents the continuous degeneration of the dopaminergic 
neurons of the substantia nigra. When dopaminergic neuronal loss reaches 
>50%, cardinal motor symptoms appear (thick line) and PD becomes fully 
symptomatic (gray background). Motor symptoms worsen over time but 
respond to dopamine replenishment therapy. During the premotor phase (white 
background) non-motor symptoms (dotted line) may already be present. 
Non-motor symptoms burden also increases with time but contrary to motor 
symptoms do not respond to treatment and constitute most of the disability in 
advanced PD. Biomarkers for PD can serve three main purposes: (A) Diagnosis 
of progression to end-stage non-motor impairment, which would help predict 
bad prognosis and can serve to monitor neuroprotective therapies. (B) Positive 
diagnosis of PD by differentiating it from other causes of parkinsonism. 
(C) Presymptomatic diagnosis of PD. Although non-specific, precursor 
non-motor symptoms such as constipation, depression, hyposmia, or 
REM-sleep behavior disorders characterize a population in which future 
biomarkers for presymptomatic diagnosis should be tested.
www.frontiersin.org September 2010 | Volume 1 | Article 128 | 3
Lebouvier et al. Biomarkers for Parkinson’s disease
is minimal or absent in the olfactory bulb and no specific involve-
ment of the peripheral nervous system has been reported yet (Rub 
et al., 2002).
Altogether, these results demonstrate that PD pathology extends 
well beyond the substantia nigra and that the peripheral autonomic 
neuronal circuits are affected early, and specifically in a large pro-
portion of patients.
bIoPsable neural tIssues as a new source of 
bIomarker of PD
Remarkably, some of the extranigral structures affected by Lewy 
pathology are accessible to biopsies, making them a putative origi-
nal source of biomarkers. As the only component of the olfac-
tory system accessible to biopsy, olfactory epithelium was logically 
screened for Lewy pathology. In a pilot study, there was no evidence 
of disease-specific pathology in seven hypo/anosmic PD patients 
(Witt et al., 2009). This is probably explained by the fact that the 
pathology in the olfactory system is restricted to the olfactory bulb, 
a structure that is not accessible to routine biopsies (Parkkinen 
et al., 2009).
Quite logically, from the results obtained in autopsy specimens, 
a Japanese team attempted to retrieve Lewy pathology using routine 
skin biopsies from chest and leg. The results were disappointing 
as only two patients were positive in a series of 20 parkinsonian 
patients (Miki et al., 2010). The discrepancy between the results 
of the autopsy-based study and the in vivo study may be explained 
by the differences of the sites for tissue samples, the size of skin 
tissue examined, and the numbers of examined sections. In any 
event, this does not make the skin a source of biomarker for the 
premortem diagnosis of PD.
The two autopsy studies of the submandibular gland in LB dis-
orders raised a recent interest for the salivary glands (Beach et al., 
2010; Del Tredici et al., 2010). Apart from fine needle aspiration 
biopsies that only give access to smears of epithelial cells, histo-
logical analysis of the submandibular gland can only be achieved 
though incisional biopsy. The possibility of injury to the marginal 
mandibular branch of the facial, hypoglossal, and lingual nerves 
requires the biopsy to be performed in the operating room. Because 
of the risks and technical difficulties of such a procedure, even 
higher when it comes to the parotid gland, the analysis of the major 
salivary glands will probably never become a routine biomarker for 
PD. Conversely, minor salivary gland biopsy is safe and routinely 
performed for diagnostic purposes (Caporali et al., 2008). Provided 
that minor salivary glands recapitulate the alterations of the auto-
nomic innervation observed in the submandibular gland, which 
requires confirmation, the analysis of labial salivary glands may 
provide a useful histological biomarker (Cersosimo et al., 2010).
The ENS displays specific features that make it a prime candidate 
for being a histopathological marker of PD. In contrast to all afore-
mentioned tissues, it does not contain only postganglionic neuronal 
processes but rather is an integrated neuronal network that contains 
neurons and enteric glial cells, the counterpart of the astrocytes of 
the CNS. It is sometimes referred as a “second brain” because of 
the functional and chemical diversity of the enteric neurons that 
closely resembles that of the CNS. We have shown recently that 
whole-mounts of submucosa from routine colonic biopsies allow 
a morphological and quantitative analysis of the SMP (Lebouvier 
the ANS and be regarded as a complex postganglionic neuronal 
network. The ENS contains as many neurons as the spinal cord 
(approximately 80–100 million neurons) and the functional and 
chemical diversity of enteric neurons closely resembles that of 
the CNS (Benarroch, 2007; Cersosimo and Benarroch, 2008). 
This integrated neuronal network is organized in two ganglion-
ated plexuses, myenteric and submucosal, composed of neurons 
and enteric glial cells (Benarroch, 2007; Lebouvier et al., 2009a). 
Neurons of the myenteric plexus (or Auerbach’s) control the activity 
of the smooth muscle of the gut whereas those in the submucosal 
plexus (or Meissner’s) regulate mucosal secretion and blood flow 
(Schemann and Neunlist, 2004).
Lewy pathology has been described in the autonomic nuclei 
of the brainstem and spinal cord and in the sympathetic ganglia 
of PD patients (Wakabayashi et al., 1988, 1993; Wakabayashi and 
Takahashi, 1997; Braak et al., 2006, 2007; Braak and Del Tredici, 
2008) and ILBD subjects (Bloch et al., 2006; Minguez-Castellanos 
et al., 2007). Remarkably, LB and LN are also present in postgangli-
onic structures. Using sampled skin from the chest and forearm of 
autopsied patients, Ikemura et al. (2008) demonstrated LN in the 
sympathetic nerve fascicles of the dermis and subcutaneous tissue 
in 10 out of 14 PD patients and in one of two ILBD. The autonomic 
innervation of the submandibular gland also displays LN with a 
high sensitivity in two autopsy surveys, with lesions in 14 out of 15 
PD patients (Beach et al., 2010) and 9 of 9 PD patients respectively 
(Del Tredici et al., 2010). Moreover, LN were present in the sub-
mandibular glands of two out of three ILBD subjects (Del Tredici 
et al., 2010). Regarding the ENS, the presence of Lewy pathology 
in the gastrointestinal tract was described more than 20 years ago 
in two seminal reports (Qualman et al., 1984; Kupsky et al., 1987). 
Wakabayashi et al. (1988) found LB in the gastrointestinal tract of 
seven consecutive autopsies performed in PD patients and more 
recently Beach et al. (2010) reported LB and LN in the gut of 11 of 
17 PD patients. In both studies, the Lewy pathology was distributed 
in the MP and SMP from the upper esophagus to the rectum fol-
lowing a rostrocaudal gradient, the upper esophagus being more 
severely affected than the colon and the rectum (Wakabayashi et al., 
1988; Beach et al., 2010). Remarkably, when specific histochemical 
procedures were used (analysis of multiple slides of thick sections 
of the lower esophagus), Lewy inclusions were found in 14 out of 
15 PD patients, suggesting that the pathology is scattered but nearly 
constant in the ENS (Beach et al., 2010). Among ILBD patients, 
the rate of enteric pathology varies depending on the sampling and 
techniques used to assess the synucleinopathy, from 1/7 to 14/17 
(Bloch et al., 2006). A thorough assessment of the ENS in ILBD is 
still needed to test the hypothesis of its prime involvement during 
PD (Braak et al., 2006).
The histopathological features observed in the olfactory bulb 
and in the peripheral nervous system of PD patients are likely to 
be specific for this neurodegenerative condition. Indeed, although 
the olfactory bulb is constantly affected by the pathological proc-
ess in multiple system atrophy, the inclusions of alpha-synuclein 
are mainly glial (Kovacs et al., 2003). The Lewy pathology in the 
peripheral nervous system of multiple system atrophy patients is 
primarily preganglionic and, in contrast to PD, the postganglionic 
network is almost completely spared (Ikemura et al., 2008; Orimo 
et al., 2008; Del Tredici et al., 2010). Regarding PSP, tau pathology 
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Figure 2 | routine colonoscopy biopsies as a novel biomarker of 
Parkinson’s disease. (A) Whole mount of submucosa microdissected from a 
standard colonoscopy biopsy and immunostained with anti-neurofilament 
antibody to unravel the neural network. Colonic submucosal (Meissner’s) plexus, 
formed by ganglia and interganglionic strands, is readily apparent. A single biopsy 
performed in the ascending or descending colon gives access to a mean of 150 
neurons. Scale bar 1 mm. (B) After magnification, double labeling with antibodies 
against neurofilament (left) and phosphorylated alpha-synuclein (right) in a 
Parkinson’s disease patient reveals the presence of Lewy neurites. Up: a 
perivascular Lewy neurite. Down: a fragmented Lewy neurite inside a submucosal 
ganglion. Arrows: neurites immunoreactive for phosphorylated alpha-synuclein 
and neurofilament. Asterisks: submucosal neurons. Scale bar: 30 μm.
et al., 2009b). A single standard colonic biopsy contains an  average 
of 35 ganglia, thus allowing the analysis of approximately 150 neu-
rons (Figure 2A). Using this approach, LN were identified in the 
SMP of four out of five PD patients (Lebouvier et al., 2008) in a 
preliminary report (Figure 2B). We have therefore undertaken a 
large-scale survey to correlate the amount of enteric pathology with 
clinical PD symptoms. A total of 10 control and 30 PD patients 
were enrolled. Four routine colonic biopsies were taken from 
the ascending and descending colon during the course of a total 
colonoscopy. Lewy pathology was apparent in the colonic biopsies 
from 21 patients (72%) and in none of the controls. In favor of 
the pathogenicity of enteric pathology, pathological burden was 
correlated with an apparent neuronal loss within the submucosal 
plexus. The clinical relevance of these findings was supported by a 
correlation between pathological burden and constipation as well 
as the amount of axial and dopa-unresponsive symptoms, which 
reflect disease progression (Lebouvier et al., 2010).
conclusIon anD PersPectIves
Although Lewy pathology is absent in a minority of cases of clinical 
PD, most of which are rare genetic forms of the disease, alpha-synu-
clein is still considered to be a key player of the pathophysiology of 
PD. In the era of functional neuroimaging and molecular biology, 
histological biomarkers may still be of great interest for the diag-
nosis and management of PD because they are the only to directly 
assess the synucleinopathy in vivo. By affecting the peripheral ANS 
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part, and then a cranial spreading within the brainstem until the 
 substantia nigra is finally reached (Orimo et al., 2008; Hawkes et al., 
2009). Suitable histological biomarkers utilize the postganglionic 
neurons, which are supposed to herald the degenerative process. 
Hence beyond positive diagnosis, the next step is to use them for 
the premotor diagnosis of PD (Figure 1C). Routinely accessible 
biomarkers would allow the screening of vulnerable populations 
for Lewy inclusions before the advent of the motor symptoms. 
Delineation of the spectrum of Parkinson’s at risk patients is cur-
rently under work (Stern and Siderowf, 2010), but surely includes 
patients with REM-sleep behavior disorder. Patients above 50 years 
presenting with abnormalities in olfaction or gastrointestinal func-
tion, particularly if justifying an endoscopy, could as well be sys-
tematically assessed.
Until imaging probes for in vivo detection of alpha-synuclein 
deposition become available (Kikuchi et al., 2010), we believe 
there is a time-window for histological biomarkers in LB diseases. 
Accumulating data suggest that they should contribute to the early 
diagnosis of PD, and thus facilitate earlier diagnosis to evaluate 
neuroprotective treatments.
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early in the course of the disease, PD provides a nearly unique 
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have been used only in variant Creutzfeldt–Jakob Disease. Though 
analysis is performed in non-neural lymphoid tissue, histochemical 
(Ironside et al., 2000) and biochemical (Wadsworth et al., 2001) 
methods can identify the pathological form of the prion protein 
in tonsil biopsies from affected individuals.
To date, the search for sensitive histological biomarkers in PD 
has been hindered by the scattered pattern of inclusions in the 
peripheral ANS. Among routinely accessible tissues, the extraor-
dinary neuronal density of the ENS accounts for the higher, yet 
imperfect, sensitivity of gut biopsies to detect the pathology. The 
good correlation between pathology burden and disease severity 
makes the technique a readily available biomarker to assess disease 
progression (Figure 1A).
Yet future work is needed to test the specificity of these peripheral 
inclusions in larger series and to improve the sensitivity of the tech-
nique. Possible strategies include an increased number of colonic 
samples or the use of upper digestive tract biopsies, which add the 
potential risk of inhalation during the endoscopy. Other biopsable 
tissues such as minor salivary glands may solve the safety issues if 
they demonstrate an equal or superior sensitivity to evidence Lewy 
inclusions. Once the sensitivity is improved, the primary goal will 
be to use such biomarkers for the positive diagnosis of PD and dif-
ferential diagnosis with other forms of parkinsonism (Figure 1B).
A new conception of the neuropathology of PD supports a cen-
tripetal pattern of degeneration from postganglionic and peripheral 
autonomic neurons to their central and preganglionic counter-
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